CMP
ARKG icon

Coston McIsaac & Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Coston McIsaac & Partners’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-49
Closed -$1K – 752
2024
Q2 		$1K Hold
49
– – ﹤0.01% 685
2024
Q1 		$1K Hold
49
– – ﹤0.01% 674
2023
Q4 		$1K Sell
49
-45
-48% -$1.22K ﹤0.01% 669
2023
Q3 		$2K Buy
94
+44
+88% +$1.44K ﹤0.01% 640
2023
Q2 		$1K Hold
50
– – ﹤0.01% 715
2023
Q1 		$1K Hold
50
– – ﹤0.01% 742
2022
Q4 		$1 Hold
50
– – ﹤0.01% 711
2022
Q3 		$1K Hold
50
– – ﹤0.01% 630
2022
Q2 		$2K Buy
+50
New +$1.75K ﹤0.01% 411

Other funds holding ARKG

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Coston McIsaac & Partners's ARKG Position: Q3 2024 in Review

Coston McIsaac & Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q3 2024, closing a stake of 49 shares — an estimated $1K sold.

Coston McIsaac & Partners first reported a position in ARKG in Q2 2022 and held it in 9 quarters. The position peaked at $2K in Q3 2023. 238 funds tracked by Wall St. Rank hold ARKG as of Q3 2024.

  • Coston McIsaac & Partners reported no remaining ARK Genomic Revolution ETF position as of Q3 2024 after selling out during the quarter.
  • Coston McIsaac & Partners sold 49 ARK Genomic Revolution ETF shares in Q3 2024, an estimated $1K.
  • Coston McIsaac & Partners first reported a position in ARK Genomic Revolution ETF in Q2 2022 and held it in 9 quarters.
  • Coston McIsaac & Partners's ARK Genomic Revolution ETF position peaked at $2K in Q3 2023.
  • 238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q3 2024.

Based on Coston McIsaac & Partners's 13F filing for Q3 2024, filed 22 Oct 2024.